Drugs / Duvakitug
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 2 met primary · 1 missed | ||||||
| Phase 2 | NCT05668013 | Jan 2023 → Jan 2026 overdue | Crohn disease, ulcerative colitis | Teva Branded Pharmaceutical Products R&D, Inc. | Active not recruiting | Met primary |
| Phase 2 | NCT05499130 | Sep 2022 → Nov 2024 | Crohn disease, ulcerative colitis | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | Met primary |
| Phase 2 | NCT04545385 | Oct 2020 → Jan 2022 | asthma | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | Missed primary |
| Phase 34 trials | ||||||
| Phase 3 | NCT07184944 | Jan 2026 → Aug 2029 expected | Crohn disease | Sanofi | Recruiting | No outcome recorded |
| Phase 3 | NCT07185009 | Jan 2026 → Sep 2028 expected | ulcerative colitis | Sanofi | Recruiting | No outcome recorded |
| Phase 3 | NCT07184996 | Oct 2025 → May 2028 expected | ulcerative colitis | Sanofi | Recruiting | No outcome recorded |
| Phase 3 | NCT07184931 | Oct 2025 → May 2029 expected | Crohn disease | Sanofi | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-02-17 | Sanofi | Results Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease sanofi.com ↗
Positive results from the RELIEVE UCCD long-term extension (LTE) study (clinical study identifier: NCT05668013 ) of duvakitug, an investigational human monoclonal antibody targeting TL1A, showed durable clinical and endoscopic efficacy maintained over 44 weeks in patients with ulcerative colitis (UC) and Crohn’s disease (CD) that initially responded to the induction phase. |
| 2026-02-17 | Teva Branded Pharmaceutical Products R&D, Inc. | Results Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease tevapharm.com ↗
In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction |
| 2025-02-22 | Sanofi | Results Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease sanofi.com ↗ |
| 2025-02-22 | Teva Branded Pharmaceutical Products R&D, Inc. | Results Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease tevapharm.com ↗
In the UC cohort of the RELIEVE UCCD study, 36% (450 mg dose) and 48% (900 mg dose) of patients treated with duvakitug achieved the primary endpoint of clinical remission (mMS)* at week 14 compared to 20% treated with placebo; |
| 2025-02-18 | Teva Branded Pharmaceutical Products R&D, Inc. | Results Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO) tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live webcast at 8 am E.T. on Monday, February 24, 2025. |
| 2024-12-17 | Sanofi | Results Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease sanofi.com ↗
Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD). |
| 2024-12-17 | Teva Branded Pharmaceutical Products R&D, Inc. | Results Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease tevapharm.com ↗
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Sanofi today announce that the Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD). |
| 2024-02-20 | Teva Branded Pharmaceutical Products R&D, Inc. | Results Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting tevapharm.com ↗ |
All press releases naming this drug 14 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Duvakitug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07185009 ↗ |
| Known as | TEV-48574 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05668013 ↗ |
| Action | Inhibit | “an anti-TNF-like cytokine 1A (TL1A) monoclonal antibody” PMID 42462750 ↗ Jul 2026 |
| Modality | Monoclonal antibody | “an anti-TNF-like cytokine 1A (TL1A) monoclonal antibody” PMID 42462750 ↗ Jul 2026 |
| Route | Subcutaneous | “subcutaneous infusion” NCT04545385 ↗ |